BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 361 filers reported holding BIO-TECHNE CORP in Q1 2020. The put-call ratio across all filers is 2.10 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,728,817 | -12.1% | 40,412 | +6.2% | 0.00% | 0.0% |
| Q2 2023 | $3,105,999 | +14.0% | 38,049 | +3.6% | 0.00% | 0.0% |
| Q1 2023 | $2,724,189 | +4.1% | 36,719 | +15.8% | 0.00% | 0.0% |
| Q4 2022 | $2,616,085 | +23.5% | 31,701 | +324.9% | 0.00% | 0.0% |
| Q3 2022 | $2,119,000 | -27.2% | 7,461 | -8.9% | 0.00% | -33.3% |
| Q2 2022 | $2,909,000 | -31.1% | 8,190 | -16.0% | 0.00% | -25.0% |
| Q1 2022 | $4,224,000 | -14.1% | 9,754 | +2.1% | 0.00% | 0.0% |
| Q4 2021 | $4,918,000 | +11.1% | 9,549 | +4.5% | 0.00% | 0.0% |
| Q3 2021 | $4,425,000 | +21.4% | 9,136 | +12.9% | 0.00% | 0.0% |
| Q2 2021 | $3,645,000 | +86.6% | 8,095 | +58.3% | 0.00% | +100.0% |
| Q1 2021 | $1,953,000 | +47.0% | 5,115 | +22.3% | 0.00% | 0.0% |
| Q4 2020 | $1,329,000 | +52.4% | 4,184 | +18.8% | 0.00% | +100.0% |
| Q3 2020 | $872,000 | +2.8% | 3,521 | +9.7% | 0.00% | 0.0% |
| Q2 2020 | $848,000 | +48.3% | 3,210 | +6.5% | 0.00% | 0.0% |
| Q1 2020 | $572,000 | -12.9% | 3,015 | +0.2% | 0.00% | 0.0% |
| Q4 2019 | $657,000 | +6.3% | 3,010 | -4.7% | 0.00% | 0.0% |
| Q3 2019 | $618,000 | -3.9% | 3,157 | +2.6% | 0.00% | 0.0% |
| Q2 2019 | $643,000 | +13.8% | 3,077 | +8.6% | 0.00% | 0.0% |
| Q1 2019 | $565,000 | +48.3% | 2,834 | +7.7% | 0.00% | 0.0% |
| Q4 2018 | $381,000 | -36.0% | 2,631 | -9.7% | 0.00% | 0.0% |
| Q3 2018 | $595,000 | +32.5% | 2,913 | -4.0% | 0.00% | 0.0% |
| Q2 2018 | $449,000 | -2.0% | 3,034 | -1.2% | 0.00% | 0.0% |
| Q1 2018 | $458,000 | +40.9% | 3,072 | +21.9% | 0.00% | 0.0% |
| Q4 2017 | $325,000 | +2.8% | 2,521 | -1.0% | 0.00% | 0.0% |
| Q3 2017 | $316,000 | +14.9% | 2,546 | +8.4% | 0.00% | 0.0% |
| Q2 2017 | $275,000 | -23.6% | 2,348 | -26.4% | 0.00% | -66.7% |
| Q2 2016 | $360,000 | – | 3,189 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ownership Capital B.V. | 972,263 | $308,742,000 | 4.35% |
| Sandhill Capital Partners LLC | 138,864 | $44,096,000 | 4.03% |
| STONE RUN CAPITAL, LLC | 27,350 | $8,685,000 | 3.45% |
| DF DENT & CO INC | 925,823 | $293,995,000 | 3.42% |
| Brown Capital Management | 1,498,233 | $475,764,000 | 3.29% |
| MAIRS & POWER INC | 848,081 | $269,308,000 | 2.99% |
| Summit Creek Advisors LLC | 64,179 | $20,380,000 | 2.62% |
| GENEVA CAPITAL MANAGEMENT LLC | 402,958 | $127,959,000 | 2.17% |
| Aristotle Atlantic Partners, LLC | 86,993 | $27,625,000 | 2.13% |
| CROWN ADVISORS MANAGEMENT, INC. | 8,000 | $2,540,000 | 1.82% |